Top Page
Emyria Ltd
(Sydney:EMD)
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
Emyria Ltd Business Overview & Revenue Model
Emyria Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.77M | 2.20M | 1.59M | 1.82M | 1.98M | 1.01M |
| Gross Profit | -172.42K | -167.55K | -3.32M | -4.41M | -1.58M | -2.79M |
| EBITDA | -399.76K | -13.03M | -4.14M | -6.74M | -4.49M | -4.80M |
| Net Income | -1.63M | -11.46M | -5.13M | -7.33M | -4.91M | -5.24M |
Balance Sheet | ||||||
| Total Assets | 5.04M | 5.43M | 10.16M | 8.25M | 9.06M | 5.06M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 1.57M | 2.73M | 3.88M | 6.53M | 3.69M |
| Total Debt | 802.68K | 1.72M | 1.27M | 632.70K | 949.70K | 610.82K |
| Total Liabilities | 1.63M | 3.00M | 3.37M | 1.93M | 1.88M | 1.28M |
| Stockholders Equity | 3.41M | 2.43M | 6.79M | 6.32M | 7.18M | 3.78M |
Cash Flow | ||||||
| Free Cash Flow | -973.65K | -4.44M | -7.01M | -7.46M | -4.60M | -4.65M |
| Operating Cash Flow | -812.51K | -4.28M | -3.77M | -5.43M | -3.94M | -4.45M |
| Investing Cash Flow | -1.18M | -1.38M | -3.23M | -2.03M | -661.39K | -201.81K |
| Financing Cash Flow | 1.58M | 4.50M | 5.86M | 4.81M | 7.44M | 5.73M |
Emyria Ltd Technical Analysis
Emyria Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$18.38M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | AU$77.37M | ― | -457.46% | ― | 21.93% | 10.34% | |
54 Neutral | AU$113.13M | ― | ― | ― | ― | ||
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
51 Neutral | AU$34.36M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
47 Neutral | AU$15.83M | ― | -17.24% | ― | 34.47% | 41.83% | |
44 Neutral | AU$16.51M | ― | -74.80% | ― | -9.16% | 89.23% |
Emyria Ltd Corporate Events
Emyria Limited has announced that Tattarang Ventures Pty Ltd, along with associated entities, has ceased to be a substantial holder in the company as of June 26, 2025. This change was due to the dilution of shares following the issuance of fully paid ordinary shares pursuant to a placement, affecting 23,817,777 shares. This development may impact Emyria’s shareholder structure and could influence its market positioning and stakeholder interests.
Emyria Limited has announced the issuance of 120,206,872 new fully paid ordinary shares at $0.024 per share, which will be immediately tradable under the exemption provided by section 708A(5) of the Corporations Act. This move is part of a strategic placement to enhance the company’s financial position and operational capabilities, potentially impacting its market presence and stakeholder interests positively.
Emyria Ltd has announced the quotation of 120,206,872 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of June 26, 2025. This move is part of previously announced transactions and reflects the company’s efforts to enhance its market presence and operational capacity, potentially impacting its stakeholders by increasing liquidity and visibility in the market.
Emyria Limited has announced a landmark reimbursement agreement with Medibank, Australia’s largest private health insurer, which will provide coverage for eligible members with PTSD to access Emyria’s psychiatrist-led program at Perth Clinic. This development, highlighted at the Psychedelic Science 2025 conference, positions Emyria as a global leader in creating sustainable funding pathways for complex mental health care models, addressing significant barriers in scaling psychotherapy models.
Emyria Ltd has announced a proposed bonus issue of 166,402,206 unquoted options, exercisable at $0.05 each, with an expiration date 18 months from the date of issue. This strategic move is aimed at enhancing shareholder value and strengthening the company’s capital structure, potentially impacting its market position positively.
Emyria Limited has announced a multi-year agreement with Medibank, Australia’s largest private health insurer, to fund Emyria’s PTSD care program at Perth Clinic. This partnership marks the first major private health insurance funding for a psychotherapy-led PTSD program in Australia, validating Emyria’s Empax Model. The program, which integrates psychiatrist-supervised therapy and real-world data capture, is now accessible to eligible Medibank customers without out-of-pocket costs. This collaboration positions Emyria as a national leader in mental health care and supports its expansion strategy to establish additional centers and partnerships across Australia. The program’s outcomes will be independently evaluated by the Australian National University to support broader adoption and reimbursement.
Emyria Limited, a company listed on the Australian Securities Exchange, has requested a trading halt in its securities. This halt is pending the release of an announcement concerning a significant commercial agreement and capital raising. The trading halt is expected to remain in place until either the announcement is made or normal trading resumes on 18 June 2025. This move could have implications for Emyria’s market positioning and stakeholder interests, as it suggests potential strategic developments within the company.
Emyria Limited has announced promising six-month follow-up results from its treatment program for patients with treatment-resistant PTSD, showing significant symptom improvement and quality-of-life gains. The results highlight the effectiveness of Emyria’s structured, psychiatrist-led care model, which has shown to provide meaningful and sustained improvements in a real-world setting, positioning the company as a global leader in PTSD treatment.
Emyria Ltd has announced that David Dominic Pevcic has ceased to be a substantial holder in the company as of March 31, 2025. This change is due to the dilution of shares resulting from a placement, affecting over 20 million voting securities. The announcement reflects a shift in the company’s shareholder structure, which may influence its governance and strategic direction.
Emyria Limited reported significant clinical outcomes from its PTSD treatment program, with patients showing substantial improvements in symptoms and quality of life. The company also launched a treatment-resistant depression program, engaged with health funders for pilot programs, restructured its leadership, and expanded its treatment capacity by opening a new Empax Centre.
Emyria Limited has opened its second Empax Centre within Perth Clinic, a leading private mental health hospital in Western Australia, expanding its treatment capacity by 50%. This move is part of a broader strategy to meet growing national demand and align with healthcare funders’ requirements for evidence-based mental health therapies. The new centre will initially treat patients with PTSD and treatment-resistant depression, with plans for further expansion on the East Coast. The initiative reflects Emyria’s commitment to scalable, evidence-based care and its potential for lasting patient impact, supported by private insurers and major payers.